From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline

Mol Neurodegener. 2020 Jun 1;15(1):31. doi: 10.1186/s13024-020-00373-9.

Abstract

Amyotrophic lateral sclerosis (ALS) and Frontotemporal Degeneration (FTD) are neurodegenerative disorders, related by deterioration of motor and cognitive functions and short survival. Aside from cases with an inherited pathogenic mutation, the causes of the disorders are still largely unknown and no effective treatment currently exists. It has been shown that FTD may coexist with ALS and this overlap occurs at clinical, genetic, and molecular levels. In this work, we review the main pathological aspects of these complex diseases and discuss how the integration of the novel pathogenic molecular insights and the analysis of molecular interaction networks among all the genetic players represents a critical step to shed light on discovering novel therapeutic strategies and possibly tailoring personalized medicine approaches to specific ALS and FTD patients.

Keywords: ALS; Dementia FTLD; FTD; Genetics; Motor neuron disease TDP-43; Stem cell.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis / genetics
  • Amyotrophic Lateral Sclerosis / therapy*
  • Atrophy / genetics
  • Frontotemporal Dementia / genetics
  • Frontotemporal Dementia / therapy*
  • Humans
  • Mutation / genetics
  • Neurodegenerative Diseases / therapy*
  • Therapies, Investigational* / methods